44 results about "Omeprazole" patented technology

The present application relates to a kind of sulfide monooxygenase mutant and its application in esomeprazole synthesis.The sulfide monooxygenase mutant, its encoding gene, the preparation method of the recombinant expression vector containing the gene sequence, co-expression recombinant vector and recombinant expression transformant, and the application of the recombinant sulfide monooxygenase mutant catalyst in esomeprazole synthesis are specifically disclosed.Compared with other sulfide monooxygenases, the sulfide monooxygenase mutant obtained by the present application can efficiently utilize the coenzyme NADH with lower cost and higher stability to catalyze the asymmetric oxidation reaction of omeprazole sulfide, prepare esomeprazole, has the advantages of high substrate concentration, mild reaction condition, environment-friendly, simple operation, high yield, low production cost and good industrial application prospect.

The invention discloses a traditional Chinese medicine-probiotic combined preparation, a preparation method thereof and application of the traditional Chinese medicine-probiotic combined preparation in gastric mucosal lesion protection. The preparation is composed of a traditional Chinese medicine extract and a bacillus subtilis bacterial suspension, the traditional Chinese medicine extract is prepared from radix codonopsis, rhizoma smilacis glabrae, rhizoma atractylodis macrocephalae, fructus aurantii, radix aucklandiae, bletilla striata, herba ecliptae, radix salviae miltiorrhizae, fructus arctii and fructus psoraleae according to a specific proportion through water decoction, filtration, freeze-drying and mixing with the prepared bacterial suspension. The combined preparation has remarkable protection and treatment effects on gastric mucosal lesion caused by helicobacter pylori infection and ethanol, not only can effectively inhibit the growth of helicobacter pylori, but also can relieve gastric inflammatory response and apoptosis, and the effect of the combined preparation is equivalent to or even better than that of a conventional triple therapy or omeprazole. Meanwhile, the preparation shows synergistic interaction functions of regulating body immunity and maintaining intestinal flora balance, the preparation process is simple and convenient, the safety is high, and the preparation has wide application prospects in preparation of drugs for resisting helicobacter pylori, protecting gastric mucosa and regulating intestinal flora.

The invention discloses high-alkali-resistance glass and a preparation method and application thereof.The preparation method comprises the steps that evenly-mixed ingredients are added into a platinum crucible at the temperature of 1400-1500 DEG C, the platinum crucible is placed in a lifting furnace to be subjected to heat preservation for 60-80 min at the temperature of 1550-1580 DEG C, then the crucible is taken out, and molten liquid is poured onto a mold; after the molten liquid is formed, quickly transferring the molten liquid into an annealing furnace, keeping the temperature at 550-580 DEG C for 30 minutes, and cooling the molten liquid to room temperature along with the furnace to obtain the high-alkali-resistance glass. The corrosion rate of the prepared high-alkali-resistance glass is 7-14 mg / dm < 2 >, the alkali resistance of the high-alkali-resistance glass is far lower than the industrial standard that the alkali resistance of the high-alkali-resistance glass is smaller than or equal to 75 mg / dm < 2 >, the weight loss of the glass in a NaOH solution with the ph being larger than 12 is small, and the high-alkali-resistance glass can be used for containing strong-alkali liquid medicine such as phenytoin sodium for injection and omeprazole for injection and other injections with the ph being larger than 11. And the problems of sheet falling or influence on liquid medicine quality caused by poor alkali resistance can be avoided.

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

1. The name of the design product: packaging box (omeprazole enteric-coated tablets). 2. The use of the design product: used for the outer packaging of products. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: the unfolded state reference drawing.

The present application discloses a co-crystal of omeprazole and 2,6-dihydroxybenzoic acid, wherein the molar ratio of omeprazole to 2,6-dihydroxybenzoic acid is 1:1, and the co-crystal has higher solubility, dissolution rate, bioavailability and stability compared with omeprazole.

This invention discloses an omeprazole enteric-coated composition, which is prepared by hot melt extrusion of omeprazole, a solid lipid carrier, a surfactant, a pH-sensitive polymer, and a plasticizer to form a biphase matrix structure with the pH-sensitive polymer as the continuous phase and the omeprazole-containing lipid phase as the dispersed phase. The preparation method is also disclosed, thereby achieving gastric protection of omeprazole, rapid intestinal release, and good storage stability.

The invention belongs to the technical field of medicine and chemical production, and particularly relates to a preparation method of omeprazole. The preparation method comprises the following steps: adding omeprazole thioether, polyaniline and cobalt salt into toluene, dropwise adding a hydrogen peroxide solution, and after dropwise adding, carrying out heat preservation and stirring, cooling and crystallizing, filtering, washing and drying to obtain an omeprazole solid. The polyaniline is used as the catalyst, the cobalt salt is used as the cocatalyst, the catalyst is high in stability and high in catalytic capacity, the yield of the synthesis method is high, and over-oxidized sulfone impurities cannot be generated. The catalyst is not inactivated after being recycled for multiple times, so that the catalyst cost can be greatly reduced, and the production cost of the product is reduced. The method does not need to separate the catalyst, can be recycled by using the mother liquor, and can be developed into a continuous synthesis process.

The present invention relates to clear stable ready to use compositions of Proton pump inhibitors, in particular Omeprazole or Esomeprazole or salts thereof. The invention also provides a process to prepare these compositions.

This invention provides a method for preparing a proton pump inhibitor thioether intermediate. The method involves reacting 3,5-dimethyl-4-methoxy-2-pyridinemethanethiol as a raw material with paraformaldehyde to obtain an intermediate, which is then further reacted with 4-methoxy-o-phenylenediamine, followed by post-treatment to obtain omeprazole thioether. This preparation method is novel, simple to operate, produces a high-purity product, and is suitable for industrial production.

The present application discloses a co-crystal of omeprazole and 3,5-dinitrobenzoic acid, wherein the molar ratio of omeprazole to 3,5-dinitrobenzoic acid is 1:1, and the co-crystal has higher stability, in-vivo absorption speed and onset speed compared with omeprazole.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The invention particularly relates to an escomeprazole magnesium enteric-coated particle and a preparation method thereof. The esomeprazole magnesium enteric-coated particles are particles prepared from a pellet core material by a fluidized bed coating medicine carrying layer, an isolating layer and an enteric-coated layer in sequence, the drug carrying layer is prepared from a laminated suspension, the isolation layer is prepared from an isolation pill suspension, the enteric-coated layer is prepared from an enteric-coated pill solution, and escomeprazole magnesium is enriched in the drug carrying layer. According to the preparation method, an aqueous dispersion membrane control technology is adopted, and a multi-unit esomeprazole magnesium enteric-coated particle administration form is adopted, so that burst release is not easy to occur, and the safety is high. The escomeprazole magnesium enteric-coated particles which are stable in quality, smaller in particle size, free of sand feeling during oral administration and higher in compliance are obtained by combining air jet pulverization with fluidized bed liquid phase lamination and microencapsulation technologies, and are suitable for being taken by children.

The invention provides an omeprazole enteric capsule and a preparation method thereof, and belongs to the technical field of medicines. The omeprazole enteric-coated capsule is prepared by taking an omeprazole derivative as an active component and embedding the omeprazole derivative through a sustained-release enteric-coated material. According to the omeprazole enteric capsule prepared by the invention, by adjusting the molecular structure of omeprazole, the water solubility and the bioavailability of omeprazole are improved, the half-life period is prolonged, and by embedding the sustained-release enteric material, the targeted slow release of intestinal tracts is realized, so that the drug effect time is prolonged, the problem of repeated medication is avoided, the compliance of patients is improved, and the bioavailability of the omeprazole enteric capsule is improved. Wide application prospects are realized.

This invention provides a quetiapine fumarate tablet composition and its preparation method. The composition contains the following components: quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product, povidone, calcium hydrogen phosphate, microcrystalline cellulose, sodium carboxymethyl starch, lactose monohydrate, magnesium stearate, and omeprazole. This invention also provides a method for processing a large-particle-size, highly fluid, highly soluble, and stable active pharmaceutical ingredient (API). This involves adding the API to a hydroxypropyl-β-cyclodextrin solution, homogenizing the resulting suspension, and spray-drying to prepare the quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product. The resulting intermediate powder obtained by wet granulation of the above-mentioned API-containing product exhibits superior flowability, smaller relative standard deviation of content uniformity, and a faster tableting rate after compression compared to tablets prepared solely from large-particle-size APIs, which is highly beneficial for industrial-scale production.

To provide a pediatric suspension formulation.SOLUTION: The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.SELECTED DRAWING: None

The utility model relates to the technical field of omeprazole production, and discloses a transfer device for omeprazole production, which comprises a base, a mounting seat fixedly mounted at the upper part of the base, a storage barrel fixedly mounted at the upper part of the mounting seat, a barrel cover arranged at the upper part of the storage barrel, and a feed pipe communicated with the upper part of the barrel cover, the discharging pipe is arranged at the bottom of the storage barrel in a communicating mode, the connecting assembly is arranged on one side of the base and comprises a protection mechanism arranged on the upper portion of the base, a moving mechanism is arranged at the bottom of the base, and a valve is arranged at the outlet end of the discharging pipe. The problems that an existing transfer device does not have a protection effect, a storage barrel is prone to being broken due to external force in the rotating process, reagent leakage is caused, manual cleaning of the interior of the storage barrel is inconvenient, residual reagent is prone to going bad, follow-up use of the storage barrel is affected, and the applicability of the device is affected are solved.

The present invention provides a method for preparing omeprazole sulfide. The method uses 2-chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride as a raw material and reacts it with thiocyanate to obtain an intermediate, which is then further reacted with p-methoxyphenylhydrazine and post-treated to obtain omeprazole sulfide. The preparation method is novel, simple to operate, and produces a high-purity product, making it suitable for industrial production.

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, and anticancer adjuvants, comprising omeprazole (KN510) browning substance.In the present invention, omeprazole browning substance (acid degradation substance) was prepared by treating conventional omeprazole with acid, and when the prepared omeprazole browning substance (acid degradation substance) was treated on a pancreatic cancer cell line, etc, it was confirmed that the anticancer effect was significantly increased compared to conventional omeprazole. Therefore, the omeprazole (KN510) browning substance (acid degradation substance) of the present invention can be utilized as a composition for preventing or treating cancer, or as an anticancer adjuvant.

The present invention relates to a coated tablet composition comprising omeprazole (KN510) with improved stability and a method for preparing the same. More specifically, the present invention relates to a bilayer coated tablet composition comprising omeprazole, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, and a method for preparing the same. In the present invention, in order to increase the stability of a KN510 tablet (30 mg) comprising omeprazole, a tablet composition is designed using calcium carbonate. It is proved that when mannitol and lactose are contained as excipients, tablets satisfying disintegration, dissolution and friability standards can be prepared, and the increase of related substances is significantly reduced.

The present invention relates to a novel two-component formulation of an active ingredient, especially a proton pump inhibitor. The two-component formulation is stable for extended periods on storage, and the components are combined to give a formulation that is suitable for oral administration, having good palatability and efficacy.

This invention discloses an esomeprazole sodium and its purification method, relating to the field of drug synthesis technology. The purification method includes the following steps: S1, mechanically grinding crude esomeprazole sodium with a composite solid purification additive to obtain an activated mixture; the composite solid purification additive is a composition of diisopropyl tartrate and hydroxypropyl-β-cyclodextrin, and the mass ratio of diisopropyl tartrate to hydroxypropyl-β-cyclodextrin is (1~5):(2~4); S2, adding a washing solvent to the activated mixture and stirring and washing, then performing solid-liquid separation to obtain a solid wet product; the washing solvent includes ethyl acetate, methyl tert-butyl ether, or isopropyl ether; S3, drying the solid wet product to obtain purified esomeprazole sodium. This purification method is not only simple in process and has a high product yield, but also does not introduce new impurities, and the product has high optical and chemical purity.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

The present invention provides an omeprazole enteric-coated capsule and a preparation method thereof. The omeprazole enteric-coated capsule comprises omeprazole enteric-coated pellets and a capsule shell. The omeprazole enteric-coated pellets sequentially comprise, from the inside to the outside: a blank drug core layer, a first protective layer, a drug-loading layer, a second protective layer, an isolation layer and an enteric-coated layer. For the omeprazole enteric-coated capsule prepared by the present invention, through the introduction of the first protective layer, the second protective layer, an alkalizing agent, etc., the drug has good stability and release property.

The invention relates to an external traditional Chinese medicine composition for treating liver-stomach disharmony type epigastric pain, which is prepared from the following raw material medicines in parts by weight: 18-22 parts of fructus evodiae, 7-11 parts of cinnamon, 7-11 parts of ginger, 7-11 parts of clove, 10-14 parts of ligusticum wallichii, 13-17 parts of corydalis tuber and 13-17 parts of fingered citron. The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for treating liver-stomach disharmony type epigastric pain. The invention further provides a pharmaceutical composition for treating liver-stomach disharmony type epigastric pain. The pharmaceutical composition is prepared from the traditional Chinese medicine composition, omeprazole enteric capsules and mosapride citrate tablets. The acupoint application can improve the traditional Chinese medicine syndromes of patients with liver-stomach disharmony type epigastric pain, reduce epigastric pain attack times and pain degree, inhibit inflammatory response and reduce the recurrence rate.

Omeprazole is used as a widely applied proton pump inhibitor and is mainly used for treating various diseases caused by hyperacidity, such as gastric ulcer, duodenal ulcer, reflux esophagitis and the like. The invention relates to a novel application of a commercially available medicine omeprazole, namely the omeprazole has remarkable anti-aging activity. The research on model organism caenorhabditis elegans finds that omeprazole can significantly prolong the life of nematodes. Specifically, when the nematodes are cultured in culture media containing 1.6 mg / mL omeprazole and 3.2 mg / mL omeprazole, the service lives of the nematodes are prolonged by 47.80% and 61.51% respectively, and the effect is extremely rare in current drug research.

The present application provides a method for detecting surface defects of omeprazole enteric-coated capsules, which belongs to the field of artificial intelligence technology. The method comprises: an electronic device acquires M images of the omeprazole enteric-coated capsules, where the M images are multiple images taken during the process of the omeprazole enteric-coated capsules rotating on the same axis, and M is an integer greater than 1; the electronic device extracts features of each of the M images through a neural network model, and fuses the features of each of the M images to obtain fused features of the M images; the electronic device processes the fused features of the M images through the neural network model to obtain a processing result, and the processing result indicates whether there are defects on the surface of the omeprazole enteric-coated capsules.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.

1. The name of the product of this design: packaging box (omeprazole enteric-coated capsules). 2. Purpose of this design product: used for product packaging. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: reference picture of the expanded state.

The present invention discloses an omeprazole enteric-coated capsule and a preparation method thereof. First, sodium citrate, soybean phospholipid and omeprazole are mixed to obtain a functional liquid. Then, mannitol, lactose, corn starch, antioxidant, chelating agent and hydroxypropyl methylcellulose are mixed to form a granulation mixture. The granulation mixture and the functional liquid are mixed, made into wet pellets and then dried, and the medicated pellets are collected. Then, an isolation layer coating and an enteric layer coating are carried out, and finally they are filled into capsules to obtain the omeprazole enteric-coated capsule. Compared with the prior art, the enteric-coated capsule prepared by this method has good solubility and stability, can protect the drug under the influence of gastric acid, and improve the bioavailability of the drug.